Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
66.00    -0.50 (-0.75%)
Bid:
65.00
Ask:
67.00
Spread: 2.00 (3.077%)
Market Cap: £16.08m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

20 Jan 2026 07:00

RNS Number : 4533P
MyCelx Technologies Corporation
20 January 2026
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

20 January 2026

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

MYCELX Achieves Profitability in 2025 Outperforming Market Expectations

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to provide a year-end financial update, reporting expected profitability that significantly exceeds market expectations, along with an update on the Company's strategy for its core markets.

 

The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million.

 

While EBITDA and profit before tax ('PBT') remain subject to year-end closing procedures, the Company expects EBITDA to be in the region of $680,000, a 131% improvement over FY2024, which includes a gain of $160,000 from the sale of its Saudi Arabia operations, and $520,000 without the gain, compared to market expectations of an EBITDA loss of $200,000.

 

PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.

 

This outperformance reflects strict cost discipline, operating leverage, and an increased contribution from higher-margin revenue.

 

Cash and cash equivalents at year-end are $860,000, including $50,000 restricted cash. The Company also expects to collect approximately $4 million in cash during Q1 2026.

 

Current Trading and Outlook

 

We enter 2026 with a stronger earnings profile, a streamlined organization, and increasing commercial momentum across our core markets in the U.S. and internationally. The actions taken in 2024 and executed in 2025 have repositioned the Company for faster customer adoption, multiple project wins, and improved cash generation. Our relationships in the Middle East remain strong, and traction in the U.S. is accelerating following successful trials and deployments with both existing and new customers. We remain disciplined in capital allocation and margin expansion as we scale the business and focus on delivering sustainable, long-term value.

 

While the Company is optimistic about the prospects for 2026 and beyond, at this point in the year the company is maintaining current year guidance and will update the market in due course when there is greater visibility on a number of major contracts.

 

Strategic Update

 

The Company's core markets have been refined to concentrate on Produced Water, PFAS and Water Services (industrial water treatment) as the key focus markets. Produced Water treatment remains the primary focus. PFAS Remediation is slowly evolving into a major market, and the Company is engaged in specific verticals within PFAS that currently have budget to spend. In the case of Water Services, the Company has been selling legacy products into niche applications that add high margin revenue and growing that incremental business will be achieved by expanding roles and repositioning current personnel.

 

The Board was pleased to elevate Matthew Goysich, Director of Engineering, to Executive Vice President and Jim Weidler, to Executive Vice President of Business Development. Both executives have joined the Executive Management team and will attend Board Meetings to provide their insight on our core markets and commercial and strategic plan progress. We congratulate both Matthew and Jim on their well-earned promotions.

 

The Company will make new hires this year in Engineering and Business Development in Q1. The engineering hire will allow Matthew to spend more time with key clients, closing sales and influencing tactics and strategy. Driving our business in the Permian Basin requires an experienced sales professional with relationships and water experience. This initiative and overall sales and marketing reporting and activity will be managed by Jim Weidler.

 

Connie Mixon, CEO, commented:

 

"Achieving profitability represents an important inflection point for MYCELX. Our reputation for delivering advanced technology that economically provides better performance is increasingly recognized among key market players globally. We are excited to continue to vigorously execute our successful strategy to win more business and strengthen our financial profile as we create long-term value for all stakeholders".

 

 

For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Callum Davidson / Elysia Bough (Corporate Finance)

Harriet Ward (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKCBBDBKDKDD
Date   Source Headline
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity
28th Feb 20194:54 pmRNSResults of Fundraising
28th Feb 20197:00 amRNSProposed $1.8 million Placing
13th Feb 201910:22 amRNSTrading Update
21st Dec 20187:00 amRNSHolding(s) in Company
11th Dec 20187:15 amRNSDirectorate Changes
7th Dec 20187:00 amRNSBlock Admission Interim Update
29th Nov 20187:00 amRNSNew Project Award and Trading Update
8th Oct 20187:00 amRNSNew Project Award and Trading Update
12th Sep 20187:00 amRNSHalf Year Results Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.